BCL2 and B-cell chronic lymphocytic leukemia: Therefore, treating CLL patients solely with Bcl-2 inhibitors might not fully address the disease complexity, often requiring the use of combined treatment with inhibitors of Bruton tyrosine kinase (BTK) such as ibrutinib and acalabrutinib [39,40,41,42,43,44].